Who can use Hernexeos(Zongertinib)?

HERNEXEOS is indicated for adult patients with advanced non-squamous non-small cell lung cancer harboring specific HER2 mutations.

Approved Use

This medication is approved for the treatment of adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC). Its use is specifically contingent upon the presence of HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as identified by an FDA-approved test. Furthermore, patients should have received at least one prior systemic therapy. This indication received accelerated approval based on tumor response metrics.